Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Waivers of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form and Type A Medicated Articles, 38299 [2012-15721]
Download as PDF
<![CDATA[
38299
Federal Register / Vol. 77, No. 124 / Wednesday, June 27, 2012 / Notices
participants in the study Management
Information System (MIS).
Annual Burden Estimates
previously-approved field data
collection instrument, and the current
request. Burden for all instruments is
annualized over three years.
The following table provides the
combined burden estimates for the
Annual
number of
respondents
Activity/respondent
Average
burden per
response
(minutes)
Number of
responses per
respondent
Total annual
burden hours
Collection of Field Data (Approved April 20, 2012)
Selecting Study Grantees Discussions/grantee and partner organization
staff ...........................................................................................................
50
1
60
50
30
2,105
70.2
1
10
10
351
351
2,000
1
30
2,517
2
Introductory Script and Baseline Survey (Currently Requested)
Introductory Script:
(1) Grantee staff ...................................................................................
(2) Program applicants .........................................................................
Baseline Survey:
(1) Study participants ...........................................................................
1.000
Study MIS (Currently Requested)
Study MIS:
(1) Grantee staff ...................................................................................
30
Estimated Total Annual Burden
Hours: 4,269.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Additional Information
Food and Drug Administration
Copies of the proposed collection may
be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research,
and Evaluation, 370 L’Enfant
Promenade SW., Washington, DC 20447,
Attn: OPRE Reports Clearance Officer.
All requests should be identified by the
title of the information collection. Email
address: OPREinfocollection@acf.
hhs.gov.
[Docket No. FDA–2011–N–0747]
srobinson on DSK4SPTVN1PROD with NOTICES
OMB is required to make a decision
concerning the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication. Written comments and
recommendations for the proposed
information collection should be sent
directly to the following: Office of
Management and Budget, Paperwork
Reduction Project, Email: OIRA
SUBMISSION@OMB.E0P.GOV, Attn:
Desk Officer for the Administration for
Children and Families.
Steven M. Hanmer,
Reports Clearance, Officer.
[FR Doc. 2012–15440 Filed 6–26–12; 8:45 am]
BILLING CODE 4184–37–M
19:05 Jun 26, 2012
AGENCY:
Jkt 226001
Food and Drug Administration,
HHS.
ACTION:
OMB Comment
VerDate Mar<15>2010
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Waivers of In Vivo Demonstration of
Bioequivalence of Animal Drugs in
Soluble Powder Oral Dosage Form and
Type A Medicated Articles
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Waivers of In Vivo Demonstration of
Bioequivalence of Animal Drugs in
Soluble Powder Oral Dosage Form and
Type A Medicated Articles’’ has been
approved by the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Juanmanuel Vilela, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400B, Rockville, MD 20850, 301–
796–7651,
Juanmanuel.Vilela@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On March
19, 2012, the Agency submitted a
proposed collection of information
entitled ‘‘Waivers of In Vivo
Demonstration of Bioequivalence of
Animal Drugs in Soluble Powder Oral
Dosage Form and Type A Medicated
SUMMARY:
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
2,517
Articles’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0575. The
approval expires on June 30, 2015. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
Dated: June 20, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012–15721 Filed 6–26–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0357]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Medical Device
Decision Analysis: A Risk-Tolerance
Pilot Study
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
SUMMARY:
E:\FR\FM\27JNN1.SGM
27JNN1
]]>Agencies
[Federal Register Volume 77, Number 124 (Wednesday, June 27, 2012)]
[Notices]
[Page 38299]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-15721]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0747]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Waivers of In Vivo Demonstration of
Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form and
Type A Medicated Articles
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Waivers of In Vivo Demonstration
of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form
and Type A Medicated Articles'' has been approved by the Office of
Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: Juanmanuel Vilela, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-7651,
Juanmanuel.Vilela@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On March 19, 2012, the Agency submitted a
proposed collection of information entitled ``Waivers of In Vivo
Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral
Dosage Form and Type A Medicated Articles'' to OMB for review and
clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor,
and a person is not required to respond to, a collection of information
unless it displays a currently valid OMB control number. OMB has now
approved the information collection and has assigned OMB control number
0910-0575. The approval expires on June 30, 2015. A copy of the
supporting statement for this information collection is available on
the Internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: June 20, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-15721 Filed 6-26-12; 8:45 am]
BILLING CODE 4160-01-P
